Highlights

  • GI Navigator is now commercially available in Australia and the United Kingdom.
  • More than 150 tests were ordered during the Beta program.
  • Over 400 practitioners joined the waitlist, including more than 150 new to Microba.
  • Introductory pricing is A$549 in Australia and £399 in the UK.

Microba Life Sciences Limited (ASX:MAP) has announced the commercial launch of GI Navigator in Australia and the United Kingdom. The test is designed to support patients with lower gastrointestinal symptoms by combining microbiome analysis with other clinical information in one report.

About GI Navigator

GI Navigator uses a single at-home stool sample together with a 15-minute patient questionnaire. It provides full microbiome mapping, pathogen screening and an assessment of gut physiology, with results available within two to four weeks.

Chief Scientific Officer A/Prof Lutz Krause said GI Navigator brings together Microba's microbiome technology and years of clinical data, combining the microbiome, gut physiology, pathogen screening and the patient's own symptoms in one report.

Early Demand and Pricing

More than 150 tests were ordered during the beta program. Over 400 practitioners joined the waitlist, including more than 150 who are new to Microba.

The test is offered at an introductory price of A$549 in Australia and £399 in the UK. As at 30 June 2026, Microba's practitioner network included more than 900 clinicians in Australia and over 300 in the UK.

Market Opportunity

Microba states that GI Navigator addresses about 82 million patients each year with lower GI symptoms across seven major markets.

The company notes that about half of these patients do not achieve symptom resolution through routine care, and that 40% of the population lives with an ongoing functional gut disorder.

Key Takeaways

  • GI Navigator has launched commercially in Australia and the UK.
  • The beta program generated more than 150 test orders and a waitlist of over 400 practitioners.
  • Introductory prices are A$549 in Australia and £399 in the UK.
  • Microba targets about 82 million patients a year with lower GI symptoms across seven major markets.